Clinical efficacy evaluation and prevention of adverse reactions in a randomized trial of a combination of three drugs in the treatment of cancerous pudendal neuralgia

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100046045

Enrollment

Unknown

Registered

2021-05-02

Start date

2019-06-01

Completion date

Unknown

Last updated

2021-12-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancerous pudendal neuralgia

Interventions

Experimental group:Celecoxib combined with OxyContin and Pregabalin

Control group:OxyContin and Pregabalin

Eligibility

Sex/Gender

All

Age

18 Years to 69 Years

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed as having malignant tumors with advanced tumors of pudendal neuralgia; 2. No history of opioid abuse before admission; 3. No history of mental illness, capable of verbal expression, can accurately express pain; 4. Estimated survival time greater than 4 weeks;

Exclusion criteria

Exclusion criteria: 1. Patients with nausea and vomiting, indwelling catheterization, and intestinal obstruction before admission; 2. Pregnant and lactating women; 3. Those allergic to the drugs used in this study; 4. Severe gastrointestinal diseases and cardiac insufficiency.

Design outcomes

Primary

Measure	Time frame
NRS score;	—

Secondary

Measure	Time frame
The dose of OxyContin applied;The occurrence of adverse reactions;	—

Countries

China

Contacts

Public ContactHou Junjie

Jilin Provincial People's Hospital

houjunjie1979@163.com+86 13804330689

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 15, 2026